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SUMMARY
Drug-resistant tuberculosis can be transmitted (primary) or develop during the course of
treatment (secondary). We investigated risk factors for each type of resistance. We compared
all patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two
time-periods (1993–1994 and 1998–2000) with patients with fully sensitive tuberculosis, examining
separately patients without and with previous tuberculosis (a proxy for primary and secondary
drug-resistant tuberculosis). Patients with previous tuberculosis smear positivity and arrival in
the United Kingdom<5 years were strongly associated with multidrug resistance and isoniazid
resistance. In patients with no previous tuberculosis HIV infection, residence in London and
foreign birth were risk factors for multidrug resistance, and non-white ethnicity, residence in
London and HIV infection for isoniazid resistance. Risk factors for each type of resistance diﬀer.
Elevated risks associated with London residence, HIV positivity, and ethnicity were mainly seen
in those without previous tuberculosis (presumed transmission).
INTRODUCTION
Drug-resistant tuberculosis is a threat to tuberculosis
control worldwide [1]. In England and Wales multi-
drug resistant isolates (resistant to at least isoniazid
and rifampicin) have remained uncommon with
>2% of isolates multidrug resistant [2, 3]. However,
these cases are important because they are diﬃcult
to treat and consume valuable health resources [4].
Approximately 6% of isolates in England and Wales
are isoniazid resistant [2, 3].
It is important to distinguish between drug resist-
ance due to treatment failure (acquired or secondary
resistance) and drug resistance due to transmission
of resistant strains (initial or primary resistance).
Most (but not all) patients who have drug-resistant
disease and have been treated for tuberculosis in the
past have acquired resistance as a result of inadequate
treatment ; conversely most patients with resistant
strains at the beginning of treatment who have no
prior history of tuberculosis treatment have primary
resistance as a result of transmission of a resistant
strain. Risk factors for the two pathways to drug-
resistant tuberculosis are likely to diﬀer.
Internationally, studies have consistently found
resistance to be strongly related to previous treat-
ment [5, 6]. HIV has been found to be a risk factor
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for resistance in the United States [5, 7–9] but not
in Africa [10]. Some studies have found resistance
to be associated with cavitatory pulmonary disease
[11], and most studies from developed countries
(particularly the United States) have found relation-
ships with ethnic groupings [5, 7], foreign birth [7,
12–14] and urban centres [13]. In the United Kingdom
surveillance data from England and Wales have gen-
erally shown an excess of drug-resistant cases in
London, in HIV-positive cases, those not born in the
United Kingdom and sometimes in non-white ethnic
groups [2, 3, 15].
We aimed to investigate the previously found
associations in the United Kingdom between ethnic
groups, foreign born, HIV infected, London residents
and drug-resistant tuberculosis by stratifying tu-
berculosis patients by a previously recorded episode
of tuberculosis as a proxy for primary (transmitted)
and secondary (through treatment) pathways to drug
resistance. To maximize power, and investigate any
diﬀerences in risk factors over time, we combined data
for two periods with linked laboratory and surveil-
lance data: 1993–1994 and 1998–2000.
METHODS
During 1993–1994 a national surveillance scheme for
drug sensitivity results was established (Mycobnet)
[16]. In 1995 clinicians were asked to provide more
detailed risk factor information on all drug-resistant
cases and a random sample of age-matched (<40
years, o40 years) fully sensitive controls identiﬁed
through the 1993 National Tuberculosis Survey
(NTS) and Mycobnet. Since the 1998 NTS [17] a
system of enhanced tuberculosis surveillance has
operated with routine linking to Mycobnet. For this
analysis tuberculosis patients with isolate infor-
mation for 1993–1994 were identiﬁed from the 1993
NTS, the newly established Mycobnet laboratory
surveillance system and the 1995 questionnaire.
Tuberculosis patients with isolate information for
1998–2000 were identiﬁed from enhanced tubercu-
losis surveillance for England and Wales and Mycob-
net. Resistance was determined using the resistance
ratio method on Lowenstein–Jensen media or modi-
ﬁed proportion method on liquid media (Bactec
460; Becton Dickinson, Sparks, MD, USA) [18, 19].
To optimize information available for analysis of
risk factors and to remove possible duplicate infor-
mation (from multiple isolates on the same indi-
vidual), isolates in Mycobnet for which there was
no corresponding surveillance record were deleted.
Where there was more than one isolate available for
an individual the ﬁrst was used. HIV status for both
1993–1994 data and 1998–2000 data was ascertained
by matching with the Public Health Laboratory
Service HIV and AIDS register using Soundex codes
and dates of birth. At analysis subjects with no
recorded HIV status were classiﬁed as HIV negative,
subjects with no recorded history of tuberculosis were
classiﬁed as ‘no previous tuberculosis ’, and subjects
with no smear result recorded were assumed to be
smear negative. World region of origin was examined
using World Bank/Global Burden of Disease cate-
gorizations [20].
Risk factors for multidrug-resistant tuberculosis
and isolated isoniazid resistance were ﬁrst examined
in a univariate analysis (controlling for the stratum
matching for age for 1993–1994). Risk factors were
then examined by multiple logistic regression to
control for other confounding variables. In both
univariate and multivariate analysis comparisons
were between isolated isoniazid resistance (resistance
to isoniazid without resistance to rifampicin, pyrazin-
amide or ethambutol) and fully sensitive tubercu-
losis (sensitive to isoniazid, rifampicin, pyrazinamide
and ethambutol) and between multidrug-resistant
tuberculosis (resistance to at least isoniazid and
rifampicin) and fully sensitive tuberculosis (as above).
Individuals with other resistance patterns were ex-
cluded from analysis. Final multivariate models were
selected by backward elimination of variables from
full models. An age term was ﬁtted in all models
to allow valid comparison between age-frequency
matched and non-matched data from the two time-
periods. Time-period interaction terms were ﬁtted
to examine diﬀerences in eﬀects in the two time-
periods for the following variables : sex, HIV infec-
tion, foreign birth, ethnicity and London residence.
To allow comparison of the importance of potential
risk factors for drug resistance in the four analyses
(multidrug or isolated isoniazid resistance, and pri-
mary or acquired resistance) factors that were stat-
istically signiﬁcant in at least one model are included
in all the multivariate models presented. All analyses
were performed in STATA version 7.0 [21].
RESULTS
In total there were 9541 subjects with either multi-
drug-resistant, isolated isoniazid-resistant or fully
sensitive initial isolates included in the analysis.
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Thirty patients were excluded from analysis because
of another resistance pattern (mostly isolated rifam-
picin resistance). From the 1993–1994 period there
were 615 subjects : 56 with multidrug resistance,
248 with isolated isoniazid resistance and 311 age-
matched controls with fully sensitive isolates. From
the 1998–2000 period there were 8926 subjects : 84
with multidrug resistance, 453 with isolated isoniazid
resistance and 8389 with fully sensitive isolates.
Overall 693 (7.3%) were recorded as having had
tuberculosis previously. In the unmatched prevalent
data from 1998–2000 the proportion of previous
tuberculosis patients with multidrug resistance was
4.9% and with isolated isoniazid resistance 4.7%.
In patients with no previous tuberculosis the pro-
portion with multidrug resistance was 0.7% and with
isolated isoniazid resistance 5.1%.
Univariate associations
There was a strong association between previous
treatment and multidrug resistance (OR 9.1, 95%
CI 6.3–13.2). This overall relationship was weaker
for isolated isoniazid resistance (OR 1.6, 95% CI
1.2–2.1).
Risk factors for isolated isoniazid-resistant tu-
berculosis compared with fully sensitive tuberculosis
for subjects with previous tuberculosis and with no
previous tuberculosis are given in Table 1. Risk fac-
tors for multidrug-resistant tuberculosis compared
with fully sensitive tuberculosis for subjects with pre-
vious tuberculosis and with no previous tuberculosis
are given in Table 2.
Multivariate analysis
Risk factors for multidrug-resistant tuberculosis and
isoniazid-resistant tuberculosis did not vary greatly
by individual World Bank region, and numbers in
some regions were small (or zero) so we took forward
to multivariate analysis a variable measuring length
of time since arrival in the country with a base categ-
ory of born in the United Kingdom rather than region
of origin.
Risk factors for isoniazid-resistant tuberculosis
Risk factors for isoniazid resistance in patients with
previous tuberculosis and no previous tuberculosis
are presented in Table 3.
No previous tuberculosis
In patients with no history of tuberculosis the most
important risk factor for isoniazid resistance was
ethnicity. Compared with the white ethnic group
adjusted odds ratios were similar in ethnic groups
from the Indian sub-continent (OR 1.6, 95% CI
1.2–2.1), Black Africans (OR 1.7, 95% CI 1.2–2.4)
and other non-white ethnic groups combined (OR
1.9, 95% CI 1.3–2.8). London residence was also
associated (OR 1.4, 95% CI 1.1–1.7). There was
interaction between time-period and HIV infection
(P=0.026). HIV infection was a signiﬁcant risk factor
(OR 2.4, 95% CI 1.1–5.2) in 1993–1994 but not in
1998–2000 (OR 1.0, 95% CI 0.6–1.6).
Previous tuberculosis
Smear-positive status was the most important risk
factor for isoniazid-resistant disease in subjects with
a history of tuberculosis (OR 3.2, 95% CI 1.1–9.2).
Those of non-UK origin arriving in the last 10 years
were at increased risk of isoniazid resistance com-
pared with those born in the United Kingdom
(OR 3.2, 95% CI 1.4–7.0) and this was particularly
marked for those arriving in the United Kingdom
5–9 years prior to diagnosis (OR 5.3, 95% CI
1.2–23.5). There was a non-signiﬁcant association
between London residence and isoniazid resistance.
Other variables such as HIV status, ethnicity and
gender were not predictors of isoniazid drug re-
sistance.
Risk factors for multidrug resistance
Risk factors for multidrug resistant tuberculosis in
patients with previous tuberculosis and no previous
tuberculosis are presented in Table 4.
No previous tuberculosis
Important risk factors for multidrug resistance in
subjects without a history of previous tuberculosis
included being HIV positive (OR 2.5, 95% CI
1.2–5.2), and London residence (OR 2.0, 95% CI
1.2–3.3). Non-UK origin was also important with
the risk of multidrug-resistant disease higher for
those arriving in the last 5 years (OR 3.2, 95% CI
1.4–7.3) and decreasing with duration of residence
in the United Kingdom. There were no signiﬁcant as-
sociations between multidrug resistance and ethnicity,
gender and smear-positive disease. There was strong
interaction between time-period and foreign birth
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Table 1. Risk factors for isolated isoniazid drug-resistant tuberculosis 1993–1994 and 1998–2000 by previous
tuberculosis: univariate analysis
Previous tuberculosis No previous tuberculosis
Risk factor
Isoniazid
resistance
(N=63)
n (n/N%)*
Fully
sensitive
(N=576)
N (n/N%)
OR#
(95% CI)
Isoniazid
resistance
(N=638)
n (n/N%)
Fully
sensitive
(N=8124)
n (n/N%)
OR#
(95% CI)
Age group$
0–19 years 0 (0) 37 (7) 0.0 44 (10) 604 (8) 1.0 (0.7–1.4)
20–39 years 12 (44) 181 (33) 1.0 (ref.) 244 (57) 3464 (44) 1.0 (ref.)
40–59 years 5 (19) 129 (24) 0.5 (0.2–1.7) 99 (23) 1832 (23) 0.8 (0.6–1.0)
60–79 years 9 (33) 161 (29) 0.8 (0.3–2.0) 29 (7) 1549 (20) 0.3 (0.2–0.4)
o80 years 1 (4) 39 (7) 0.4 (0.0–3.1) 10 (2) 390 (5) 0.4 (0.2–0.7)
Sex
Male 32 (51) 323 (56) 0.8 (0.5–1.4) 368 (58) 4587 (57) 1.1 (0.9–1.3)
Female 31 (49) 253 (44) 268 (42) 3519 (43)
Site
Pulmonary 37 (62) 444 (77) 0.5 (0.3–0.8) 376 (62) 5345 (66) 0.8 (0.7–1.0)
Extrapulmonary 23 (38) 129 (23) 231 (38) 2726 (34)
HIV status
Positive 3 (5) 15 (3) 1.6 (0.4–6.0) 39 (6) 264 (3) 1.7 (1.2–2.4)
Negative (or unrecorded) 60 (95) 561 (97) 599 (94) 7860 (97)
London
Resident 33 (52) 191 (33) 2.2 (1.3–3.9) 336 (53) 3227 (40) 1.5 (1.3–1.8)
Non-resident 30 (48) 385 (67) 296 (47) 4889 (60)
Smear status
Positive 27 (43) 249 (43) 1.0 (0.6–1.7) 209 (33) 2730 (34) 1.0 (0.8–1.2)
Negative or unrecorded 36 (57) 327 (57) 429 (67) 5394 (66)
Ethnic group
White 21 (33) 248 (44) 1.0 (ref.) 133 (22) 2673 (34) 1.0 (ref.)
Indian sub-continent 24 (38) 215 (38) 1.4 (0.7–2.7) 239 (40) 2966 (38) 1.4 (1.1–1.8)
African 11 (17) 71 (12) 1.5 (0.5–4.5) 156 (27) 1492 (19) 1.5 (1.2–2.0)
Other 6 (10) 36 (6) 1.5 (0.4–5.3) 67 (11) 634 (8) 1.6 (1.2–2.2)
Origin
Non UK-born 37 (64) 279 (51) 1.6 (0.9–2.9) 393 (72) 4411 (62) 1.4 (1.2–1.7)
UK-born 21 (36) 266 (49) 155 (28) 2742 (38)
Global region of origin
Established market economies· 22 (40) 282 (55) 1.0 (ref.) 168 (32) 2948 (44) 1.0 (ref.)
Former socialist 1 (2) 6 (1) 2.4 (0.3–21.4) 6 (1) 66 (1) 1.5 (0.6–3.4)
India 9 (16) 62 (12) 1.9 (0.8–4.4) 72 (14) 920 (14) 1.3 (1.0–1.8)
China 1 (2) 5 (1) 2.5 (0.3–20.5) 5 (1) 65 (1) 1.3 (0.5–3.3)
Other Asia and Islands 2 (4) 17 (3) 1.7 (0.4–8.0) 52 (10) 422 (6) 1.9 (1.3–2.6)
Sub-Saharan Africa 9 (16) 69 (13) 1.9 (0.7–5.2) 123 (24) 1212 (18) 1.5 (1.1–1.9)
Latin America & Caribbean 0 (0) 4 (1) 0.0 7 (1) 106 (2) 1.2 (0.6–2.7)
Middle Eastern Crescent 11 (20) 71 (14) 2.0 (0.8–4.6) 87 (17) 981 (15) 1.4 (1.1–1.9)
Years in the UK
Born in UK 21 (36) 266 (49) 1.0 (ref.) 155 (28) 2742 (38) 1.0 (ref.)
0–1 years 5 (9) 46 (8) 1.6 (0.5–5.3) 70 (13) 715 (10) 1.3 (1.0–1.8)
2–4 years 7 (12) 24 (5) 5.0 (1.3–18.2) 74 (14) 763 (10) 1.3 (1.0–1.8)
5–9 years 5 (9) 33 (6) 2.7 (0.8–8.5) 57 (10) 605 (8) 1.3 (1.0–1.8)
10–19 years 5 (9) 30 (6) 2.5 (0.8–7.3) 35 (6) 488 (7) 1.2 (0.8–1.7)
20–99 years 1 (2) 71 (13) 0.2 (0.0–1.3) 42 (7) 809 (11) 1.2 (0.8–1.7)
Unknown period 14 (24) 75 (14) 2.3 (1.1–5.0) 115 (21) 1031 (14) 1.8 (1.4–2.4)
* n/N%=percentage of resistant (or fully sensitive) exposed to risk factor.
# All odds ratios adjusted for age (<40,o40 years) to allow for age-matching in 1993–1994 data.
$ Excludes 1993–1994 data because of frequency matching.
· Includes UK-born.
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Table 2. Risk factors for multidrug-resistant (MDR) tuberculosis 1993–1994 and 1998–2000 by previous
tuberculosis: univariate analysis
Previous tuberculosis No previous tuberculosis
Risk factor
MDR
(N=54)
n (n/N%)*
Fully sensitive
(N=576)
n (n/N%)
OR#
(95% CI)
MDR
(N=86)
n (n/N%)
Fully sensitive
(N=8124)
n (n/N%)
OR#
(95% CI)
Age group$
0–19 years 2 (7) 37 (7) 0.6 (0.1–2.8) 5 (9) 604 (8) 0.8 (0.3–2.0)
20–39 years 16 (57) 181 (33) 1.0 (ref.) 36 (64) 3464 (44) 1.0 (ref.)
40–59 years 6 (21) 129 (24) 0.5 (0.2–1.4) 7 (13) 1832 (23) 0.4 (0.2–0.8)
60–79 years 4 (14) 161 (29) 0.3 (0.1–0.9) 7 (13) 1549 (20) 0.4 (0.2–1.0)
o80 years 0 (0) 39 (7) 0.0 1 (2) 390 (5) 0.2 (0.0–1.8)
Sex
Male 39 (72) 323 (56) 2.2 (1.2–4.1) 52 (60) 4587 (57) 1.2 (0.8–1.8)
Female 15 (28) 253 (44) 34 (40) 3519 (43)
Site
Pulmonary 43 (83) 444 (77) 1.5 (0.7–3.1) 55 (66) 5345 (66) 1.0 (0.6–1.6)
Extrapulmonary 9 (17) 129 (23) 28 (34) 2726 (34)
HIV status
Positive 4 (7) 15 (3) 2.2 (0.7–6.9) 10 (12) 264 (3) 3.6 (1.8–7.0)
Negative (or unrecorded) 50 (93) 561 (97) 76 (88) 7860 (97)
London
Resident 24 (46) 191 (33) 1.5 (0.8–2.7) 54 (64) 3227 (40) 2.4 (1.5–3.8)
Non-resident 28 (54) 385 (67) 31 (36) 4889 (60)
Smear status
Positive 35 (65) 249 (43) 2.6 (1.4–4.7) 33 (38) 2730 (34) 1.2 (0.8–1.9)
Negative or unrecorded 19 (35) 327 (57) 53 (62) 5394 (66)
Ethnic group
White 13 (25) 248 (44) 1.0 (ref.) 25 (31) 2673 (34) 1.0 (ref.)
Indian sub-continent 24 (45) 215 (38) 1.7 (0.7–4.1) 30 (38) 2966 (38) 0.9 (0.5–1.6)
African 10 (19) 71 (12) 3.3 (0.9–12.6) 22 (28) 1492 (19) 0.1 (0.6–2.3)
Other 6 (11) 36 (6) 3.1 (0.8–13.0) 3 (4) 634 (8) 0.4 (0.1–1.4)
Origin
Non UK-born 39 (76) 279 (51) 2.7 (1.4–5.5) 59 (80) 4411 (62) 2.3 (1.3–4.2)
UK-born 12 (24) 266 (49) 15 (20) 2742 (38)
Global region of origin
Established market economies· 14 (29) 282 (55) 1.0 (ref.) 20 (29) 2948 (44) 1.0 (ref.)
Former socialist economies 0 (0) 6 (1) 0.0 2 (3) 66 (1) 4.6 (1.0–20.8)
India 12 (25) 62 (12) 3.7 (1.5–8.9) 12 (17) 920 (14) 1.7 (0.8–3.6)
China 2 (4) 5 (1) 7.7 (1.4–43.6) 0 (0) 65 (1) 0.0
Other Asia and Islands 0 (0) 17 (3) 0.0 4 (6) 422 (6) 1.5 (0.5–4.4)
Sub-Saharan Africa 10 (21) 69 (13) 3.2 (1.1–9.1) 20 (29) 1212 (18) 2.5 (1.2–5.1)
Latin America & Caribbean 0 (0) 4 (1) 0.0 5 (7) 106 (2) 6.8 (2.5–18.3)
Middle Eastern Crescent 10 (21) 71 (14) 2.9 (1.1–7.3) 7 (10) 981 (15) 1.0 (0.4–2.5)
Years in the UK
Born in UK 12 (24) 266 (49) 1.0 (ref.) 15 (20) 2742 (38) 1.0 (ref.)
0–1 years 12 (24) 46 (8) 5.9 (2.0–17.5) 14 (19) 715 (10) 5.5 (2.0–14.8)
2–4 years 7 (14) 24 (5) 6.9 (1.6–29.4) 6 (8) 763 (10) 2.1 (0.7–6.5)
5–9 years 4 (8) 33 (6) 3.2 (0.9–11.3) 7 (9) 605 (8) 2.6 (0.9–7.4)
10–19 years 3 (6) 30 (6) 2.5 (0.6–9.3) 3 (4) 488 (7) 1.2 (0.3–4.5)
20–99 years 3 (6) 71 (13) 0.9 (0.2–3.3) 2 (3) 809 (11) 0.3 (0.1–1.5)
Unknown period 10 (20) 75 (14) 2.7 (1.1–7.1) 27 (36) 1031 (14) 4.7 (2.4–9.3)
* n/N%=percentage of resistant (or fully sensitive) exposed to risk factor.
# All odds ratios adjusted for age (<40,o40 years) to allow for age-matching in 1993–1994 data.
$ Excludes 1993–1994 data because of frequency matching.
· Includes UK-born.
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(P=0.016). Foreign birth was a non-signiﬁcant risk
factor for multidrug resistance during 1993–1994 (OR
1.5, 95% CI 0.6–4.1) but a strong risk factor for
multidrug resistance during 1998–2000 (OR 8.0, 95%
CI 2.6–25.4).
Previous tuberculosis
Important risk factors for multidrug resistance in
subjects with a history of previous tuberculosis
included smear-positive disease (OR 5.8, 95% CI
1.8–18.5), and non-UK origin – particularly those
who had arrived within the last 5 years in whom the
risk compared with UK-born was approximately
six-fold (OR 5.8, 95% CI 1.8–18.5). This risk ap-
peared to decrease with duration of residence in the
United Kingdom. Being HIV positive was a modest
predictor of multidrug resistance (OR 2.8) but was
not statistically signiﬁcant. Other variables including
London residence, ethnic group and gender were not
important predictors of multidrug resistance.
DISCUSSION
In this analysis of surveillance data we found that
recent migration and smear positivity were strong
Table 3. Risk factors for isolated isoniazid resistance by history of tuberculosis : multivariate analysis*
Previous tuberculosis (n=639) No previous tuberculosis (n=8762)
Risk factor OR 95% CI P value OR 95% CI P value
HIV positive 0.6 0.1–4.6 0.59 1.3 0.8–1.9 0.25
London residence 1.8 0.9–3.7 0.11 1.4 1.1–1.7 0.001
Smear-positive disease 3.2 1.1–9.2 0.03 1.1 0.8–1.4 0.55
Length of time the in UK
Born in UK 1.0 (ref.) 1.0 (ref.)
In UK<5 years 2.8 0.8–9.7 0.13 1.1 0.8–1.5 0.65
In UK 5–9 years 5.3 1.2–23.5 0.03 1.2 0.8–1.7 0.34
In UKo10 years 0.9 0.3–3.8 0.91 0.9 0.7–1.3 0.70
Ethnic group
White 1.0 (ref.) 1.0 (ref.)
Indian sub-continent 1.2 0.4–3.7 0.72 1.6 1.2–2.1 0.003
Black African 0.9 0.2–3.8 0.94 1.7 1.2–2.4 0.002
Other 0.5 0.1–2.6 0.42 1.9 1.3–2.8 0.001
* All odds ratios adjusted for age and two periods of analysis (1993–1994 and 1998–2000).
Table 4. Risk factors for multidrug resistance by history of tuberculosis: multivariate analysis*
Previous tuberculosis (n=630) No previous tuberculosis (n=8210)
Risk factor OR 95% CI P value OR 95% CI P value
HIV positive 2.8 0.6–11.9 0.17 2.5 1.2–5.2 0.02
London residence 1.2 0.6–2.4 0.67 2.0 1.2–3.3 0.006
Smear-positive disease 5.9 1.8–19.0 0.003 1.4 0.7–2.5 0.32
Length of time in UK
Born in UK 1.0 (ref.) 1.0 (ref.)
In UK<5 years 5.8 1.8–18.5 0.003 3.2 1.4–7.4 0.006
In UK 5–9 years 2.2 0.4–11.6 0.34 3.0 1.1–8.5 0.04
In UKo10 years 1.7 0.4–6.9 0.46 1.2 0.4–3.7 0.76
Ethnic group
White 1.0 (ref.) 1.0 (ref.)
Indian sub-continent 1.5 0.5–5.1 0.48 0.8 0.4–1.5 0.41
Black African 1.1 0.3–4.6 0.91 0.6 0.3–1.2 0.16
Other 1.5 0.3–6.8 0.56 0.3 0.1–0.9 0.04
* All odds ratios adjusted for age and two periods of analysis (1993–1994 and 1998–2000).
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risk factors for drug-resistant tuberculosis partly
because they were strong risk factors in patients with
presumed secondary drug resistance (from treatment
failure). Elevated risks associated with London resi-
dence, HIV infection, and ethnicity were mainly,
but not wholly, attributable to transmission. In the
presumed primary drug resistance (transmission)
group two risk factors varied by period: foreign birth
was an important risk factor for multi-drug resist-
ant diseases during 1998–2000, and HIV infection
was a risk factor for isoniazid resistance during
1993–1994.
The main strength of this study was the use of
large and representative combined microbiological
and surveillance datasets allowing adjustment for a
number of risk factors. In particular combining
data over two periods signiﬁcantly increased power
(one third of the drug-resistant cases were from the
1993–1994 period), and also allowed us to observe
changes in risk factors between periods.
The main weaknesses of our study relate to the
nature of surveillance data. For example, despite
matching with a central HIV register under-ascer-
tainment of HIV is likely. Testing for HIV on diag-
nosis of tuberculosis has only recently been strongly
recommended in the United Kingdom and recent
data from two centres in London have provided
estimates of prevalence of 11% [22] and 13% [23] ;
higher than the 5.6% prevalence amongst London
residents in our dataset. In general under-ascertain-
ment of HIV and for other risk factors should, if
it is not diﬀerential as described above, cause bias
towards the null ; we would expect a strengthening of
the association if ascertainment were improved. The
use of age-matched case-control data also restricted
some analyses and speciﬁcally made it diﬃcult to
examine age eﬀects. The use of surveillance data also
did not permit us to examine treatment compliance
and other risk factors important for understanding
resistance.
It has been increasingly recognized that at least in
areas of high transmission acquisition of new strains
can be mistaken for relapse [24, 25]. However, this is
probably less important in the United Kingdom
where recent transmission is relatively infrequent
[26]. Our ﬁndings suggest that the pathways to drug-
resistant disease are not simple and, for some risk
factors, change over time. As can be viewed in Tables
3 and 4 for several of these risk factors the diﬀer-
ences between the associations (odds ratios) for
those with previous tuberculosis and those without
is not great, although because of the much higher
numbers of subjects without previous tuberculosis
the estimates (odds ratios) for those without previous
tuberculosis are more precise. The failure to ﬁnd
clear diﬀerences between these two groups could
either be because the same risk factors are important
for both pathways to resistant disease or possibly
because of misclassiﬁcation (the previous tuberculosis
group including subjects with transmitted drug re-
sistance).
Foreign birth
The association between drug resistance and foreign
birth was particularly strong for previously treated
patients recently arriving in the United Kingdom.
A similar observation that risk of drug-resistant
disease was higher in recent arrivals to the United
Kingdom was made 40 years ago in the 1963 National
Survey [27]. However, foreign-born now consti-
tute 63% of patients reported with tuberculosis in
England, Wales and Northern Ireland [28], compared
with 26% in 1963.
Because of the relationship with recent arrival it is
probable that in part this is measuring a higher risk
of relapse with multidrug-resistant disease in those
with a history of recent treatment abroad and so
is at least partly due to interrupted treatment or
inadequate treatment in country of origin. It may
also be that this indicates a change in the pattern
of migration and less adequate treatment in groups
that have come to the United Kingdom more recently
than those who have migrated in the past.
Foreign birth was also a risk factor for multidrug
resistance without any previous tuberculosis (pre-
sumed transmission). The increased risk of multidrug-
resistant tuberculosis in patients from outside the
United Kingdom compared to those UK-born prob-
ably reﬂects higher resistance rates elsewhere [29] ;
i.e. transmission of multi-resistant strain has occurred
in the country of origin (or in transit). However,
transmission within the United Kingdom within
foreign-born groups cannot be excluded. The much
stronger relationship between foreign birth and
multidrug resistance in the 1998–2000 period may
reﬂect increased prevalence of multidrug resistance
in the countries of origin of immigrant groups in
this later period. Unfortunately we were not able to
explore the eﬀect of individual countries and regions
of origin in great detail because of lack of power,
however, the unadjusted data in Table 2 suggest
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problems with drug resistance are not conﬁned to any
single world region with elevated odds ratios for
Former Socialist Economies, Latin America and the
Caribbean, and Sub-Saharan Africa.
Ethnicity
For most of the analyses there was little associ-
ation between multidrug-resistant tuberculosis and
non-white ethnicity, therefore, after allowing for
migration/foreign birth, ethnicity in itself is no risk
factor. However, non-white ethnicity remains a risk
factor for primary isoniazid-resistant tuberculosis
(from presumed transmission). This indicates modest
increased exposure to isoniazid-resistant strains in
non-white ethnic groups. There has been a major
outbreak of isoniazid-resistant tuberculosis in the
London area covering the latter period of this study
and it may be that risk factors for isoniazid resistance
partly reﬂect the speciﬁc risk factors associated with
this outbreak [29].
HIV infection
HIV infection was more clearly a risk factor for
(primary) drug resistance associated with trans-
mission. HIV infection was signiﬁcantly associated
with multidrug resistance in those with no previous
tuberculosis. For isoniazid resistance it was a risk
factor in 1993–1994 but not for 1998–2000. The esti-
mate for the odds ratio (2.8) in those in the ‘previous
tuberculosis ’ group suggests that it may be a risk
factor for multidrug resistance but this relationship
did not reach signiﬁcance. In New York in the late
1980s and early 1990s much drug resistance in HIV-
positive patients was the result of transmission in
institutional settings such as hospitals, prisons and
residential facilities [30]. Hospital outbreaks of
multidrug-resistant tuberculosis involving several
HIV-positive patients occurred in London in 1995
[31] and 1997 [32] however, to our knowledge there
were no reported institutional outbreaks of multi-
drug-resistant tuberculosis in the United Kingdom
during the two study periods. Therefore, increased
risks of multidrug-resistant disease associated with
HIV infection may be due to exposure in non health-
care settings associated with other lifestyle features
associated with HIV infection. Plausibly the ﬁnding
that HIV is not a risk factor for isoniazid-resistant
tuberculosis in 1998–2000 is an early indication that
the advent of highly active anti-retroviral treatment
has decreased risk of exposure to drug-resistant
strains.
Alternatively the association may be a cohort
eﬀect. Since people with HIV infection progress from
tuberculosis infection to active disease faster than
immunocompetent people, the prevalence of drug
resistance in HIV-positive patients largely depends
on recently circulating strains, and so will be greater
than in HIV-negative patients when drug resistance
is increasing. However, the proportion of multidrug-
resistant isolates has been stable in the United King-
dom for many years, although this may not be the
case in other countries. It has also been postulated
that HIV-infected individuals could be more suscep-
tible to drug-resistant strains that may have reduced
virulence. However, the lack of association between
HIV and drug resistance in African studies suggests
that diﬀerences in exposure are a more important
explanation [10].
London residence
Measures of association between drug-resistant
tuberculosis and London residence were modestly
elevated in all categories, that is for those with drug-
resistant tuberculosis from presumed transmission
and treatment failure for both isoniazid- and multi-
drug-resistant tuberculosis, although associations
only reach signiﬁcance for primary drug-resistant
tuberculosis (transmission). The simplest interpret-
ation of these data is that residence in London is an
independent risk factor for exposure to drug-resistant
tuberculosis. There is no evidence that residence in
London is a strong independent predictor of treat-
ment failure.
Smear positivity
The strength of the association between smear posi-
tivity and presumed secondary drug-resistant tubercu-
losis was notable. We speculate that smear positivity
indirectly measures high bacillary load in a previous
episode of tuberculosis and this contributed to the
development of drug resistance. Subsequent presen-
tation with smear-positive disease therefore becomes
a marker of possible acquired drug resistance. This
ﬁnding has not to our knowledge been reported
before, however, the association with cavitatory dis-
ease (also associated with high bacillary load) has
been reported [11, 33]. This ﬁnding should be inter-
preted cautiously. It may be that smear positivity
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is a consequence of drug resistance rather than a
cause. However, if notiﬁcation data is being received
correctly then smear-positive status should reﬂect
status at the beginning of treatment rather than part
way into treatment. Also this relationship is much
stronger in those with previous tuberculosis than those
without, which we would not expect if the relationship
was simply due to mistaken direction of causation.
Implications for treatment and control
Recent arrivals to the United Kingdom are more
likely to have multidrug-resistant tuberculosis than
those born in the United Kingdom and this risk is
most marked in those with a history of tuberculosis.
This may constitute an additional reason both to
support international measures to ensure eﬀective
treatment in the country of origin and improve pro-
cedures at the port of entry. However, it should be
emphasized that multidrug resistance is uncommon.
Whilst it is true that the history of tuberculosis
is a very strong predictor of multidrug resistance
and within this group recent arrival in the United
Kingdom and smear-positive disease are strong pre-
dictors of multidrug resistance, the great majority of
subjects with a history of tuberculosis do not have
multidrug- or isoniazid-resistant isolates.
Among those with no previous tuberculosis, certain
subgroups – London residents, HIV positive, non-
white ethnic groups (isoniazid) and foreign born
(multidrug resistance) – appear to be at elevated risk
of being infected with drug-resistant strains and
special eﬀorts to diagnose early, manage eﬀectively
and rigorously follow-up contacts in these groups
may be needed to reduce the risk of transmission of
resistant strains.
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